Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice

European Journal of Neuroscience

Volumn 19, Issue 4, 2004, Pages 845-854

  Thiruchelvam, M J ^a   Powers, J M ^a   Cory Slechta, D A ^a   Richfield, E K ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Ageing; Gender; Mouse strain background; Paraquat; Parkinson's disease; Pesticides; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; APOMORPHINE; MANEB; MUTANT PROTEIN; PARAQUAT; PESTICIDE; TYROSINE 3 MONOOXYGENASE;

AGE DISTRIBUTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; GENETIC TRAIT; LOCOMOTION; MALE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEX RATIO; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; CELL COUNT; DOPAMINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; RATS; RISK FACTORS; SYNUCLEINS;

EID: 1542359628     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-816X.2004.03139.x     Document Type: Article

References (48)

1. Baldereschi, M., Di Carlo, A., Rocca, W.A., Vanni, P., Maggi, S., Perissinotto, E., Grigoletto, F., Amadeuci, L., & Inzitari, D. (2000) Parkinson's disease and parkinsonism in a longitudinal study. [For the ILSA Working Group.] Neurology, 55, 1358-1363.
2. Braak, H., Sandmann-Keil, D., Gai, W., & Braak, E. (1999) Extensive axonal Lewy neurites in Parkinson's disease: a novel pathologicgal feature revealed by α-synuclein immunocytochemistry. Neurosci. Lett., 265, 67-69.
3. Cho, H.J., Seiberg, M, Georgoff, I., Teresky, A.K., Marks, J.R. & Levine, A.J. (1989) Impact of the genetic background of transgenic mice upon the formation and timing of choroid plexus papillomas. J. Neurosci. Res., 24, 115-121.
4. Clarke, G., Collins, R.A., Leavitt, B.R., Andrews, D.F., Hayden, M.R., Lumsden, C.J. & Mcinnes, R.R. (2000) A one-hit model of cell death in inherited neuronal degeneration. Nature, 406, 195-199.
5. Conway, K.A., Harper, J.D. & Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nature Med., 4, 1318-1320.
6. Conway, K.A., Lee, S.J., Rochet, J.-C., Ding, T.T., Wiliamson, R.E. & Lansbury Jr., P.T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA, 97, 571-576.
7. Di Monte, D., Lavasani, M. & Manning-Bog, A.B. (2002) Environmental factors in Parkinson's disease. Neurotoxicology, 23, 487-502.
8. Ding, T.T., Lee, S.J., Rochet, J.C. & Lansbury, P.T. Jr (2002) Annular α-Synuclein protofibrils are produced wheen spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry, 41, 10209-10217.
9. Dubinsky, J. M., Kristal, B. S. & Elizondo-Fournier, M. (1995) On the probalistic nature of excitotoxic neuronal death in hipocampal neurons. Neuropharmacology, 34, 701-711.
10. Feany, M.B. & Bender, W.W. (2000) A Drosophila model of Parkinson's disease. Nature, 404, 394-398.
11. Fearnley, J. & Lees, A.J. (1991) Ageing and parkinson's disease: substantia nigra regional selectivity. Brain, 114, 2283-2301.
12. Gasser, T. (2003) Overview of the genetics of parkinsonism. Advanc. Neurol., 91, 143-152.
13. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. & Lee, V.M. (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron, 34, 521-533.
14. Gispert, S., Del Turco, D., Garrett, L., Chen, A., Bernard, D.J., Hamm-Clement, J., Korf, H.-W., Deller, T., Braak, H., Auberger, G. & Nussbaum, R.L. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunciton in the absence of aggregate formation. Mol Cell Neurosci., 24, 419-429.
15. Golbe, L.I., Dilorio, G.B.V., Miller, D.C. & Duvoisin, R.C. (1990) A large kindred with autosomal dominant Parkinson's disease. Ann. Neurol., 27, 276-282.
16. Golbe, L.I., Farrell, T.M. & Davis, P.H. (1988) Case-control study of early life dietary factors in Parkinson's disease. Arch. Neurol., 45, 1350-1353.
17. Gomez-Isla, T., Irizarry, M.C., Mariash, A., Cheung, B., Soto, O., Schrump, S., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M.A., Cha, J.H., Newell, K., Miller, D.W., Ueda, K., Young, A.B., Hyman, B.T. & Ashe, K.H. (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging, 24, 245-258.
18. Holzmann, C., Krüger, R., Vieira Saecker, A.M.M., Schmitt, I., Schöls, L., Berger, K. & Riess, O. (2003) Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm., 110, 67-76.
19. Hoskins, J.A. & Davis, L.J. ( 1989) The acute effects on levels of catecholamines and metabolites in brain, of a single dose of mptp in 8 strains of mice. Neuropharmacology, 28, 1389-1397.
20. Kahle, P.J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H.A. & Haass, C. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci., 20, 6365-6373.
21. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. & Riess, O. (1998) A30P mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet., 18, 106-108.
22. Krüger, R., Vieira-Saecker, A., Kuhn, W., Berg, D., Muller, T., Kuhn, N., Fuchs, G.A., Storch, A., Hungs, M., Woitalla, D., Przuntek, H., Epplen, J.T., Schols, L. & Riess, O. (1999) Increased susceptibility to sporadic Parkinson's disease by a certain combined α-synuclein/ apolipoprotein E genotype. Ann. Neurol., 45, 611-617.
23. Langston, J.W. (1985) I. MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life. Sci., 36, 201-206.
24. Lee, M.K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A.S., Dawson, T.M., Copeland, N.G., Jenkins, N.A. & Price D.L. (2002) Human α-synuclein-harboring familial parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation inh transgenic mice. Proc. Natl Acad. Sci. USA, 99, 8968-8973.
25. Manning-Bog, A.B., McCormack, L., Purisai, M.G., Bolin, L.M. & DiMonte, D.A. (2003) α-Synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci., 23, 3095-3099.
26. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. & Mucke, L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265-1269.
27. Matsuoka, Y., Vila, M., Lincoln, S., McCormack, A., Picciano, M. & LaFrancois, J., YuX., Dickson, D., Langston, W.J., McGowan, E., Farrer, M., Hardy, J., Duff, K., Przedborski, S. & Di Monte, D.A. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis, 8, 535-539.
28. McCormack, A.L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W., Cory-Slechta, D.A., & Di Monte, D.A. (2002) Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis., 10, 119-127.
29. Muthane, U., Ramsay, K.A., Jiang, H., Jackson-Lewis, V., Donaldson, D., Fernando, S., Ferreira, M. & Przedborski, S. (1994) Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice. Exp. Neurol., 126, 195-204.
30. 2 receptors facilitates catecholaminergic metabolism and aggravates ischemic brain damage in the rat telencephalon. Brain Res., 974, 117-126.
31. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Deheija, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I. & Nussbaum, R.L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
32. van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W.P., Ruegg, M.A., Lin, S., Caroni, P., Sommer, B., Tolnay, M. & Bilbe, G. (2000) Neuropathology in mice expressing human α-synuclein. J. Neuroscience, 20, 6021-6029.
33. Rathke-Hartlieb, S., Hahle, P.J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haas, C. & Schulz, J.B. (2001) Sensitivity to MPTP is not increased in Parkinon's disease-associated mutant α-synuclein transgenic mice. J. Neurochem., 77, 1181-1184.
34. Richfield, E.K., Thiruchelvam, M.J., Cory-Slechta, D.A., Wuertzer, C.A., Gainetdinov, R.A., Caron, M.G., Di Monte, D.A. & Federoff, H.J. (2002) Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp. Neurol., 175, 35-48.
35. Rochet, J., Conway, K.A. & Lansbury, P.T. (2000) Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α-synuclein. Biochemistry, 39, 10619-10626.
36. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C.W., Lang, I. & Masliah, E. (2002) Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and thy-1 promoters. J. Neuroscience Res., 68, 568-578.
37. Sandmann-Keil, D., Braak, H., Okochi, M., Haass, C. & Braak, E. (1999) Alpha-synuclein immunoreactive Lewy bodies and Lewy neurites in Parkinson's disease are detectable by an advanced silver-staining technique. Acta Neuropathologica, 98, 461-464.
38. Sauer, H. & Oertel, W.H. (1994) Progressive degerneration of nigrostriatal dopamine neurons following instrastriatal terminal lesions with 6-hydroy-dopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 59, 401-415.
39. Sonsalla, P.K. & Heikkila, R.E. (1988) Neurotoxic effects 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 12, 345-354.
40. Spooren, W.P., Vassout, A., Waldmeirer, P. & Gentsch, C. (1998) Differences in pre-and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahyrdopyridine-treated C57BL/6 mice as reflected in climbing activity. Eur. J. Pharmacol., 353, 1-4.
41. Stern, M., Dulaney, E., Gruber, S.B., Golbe, L., Bergen, M., Hurtig, H., Gollomp, S. & Stolley, P. (1991) The epidemiology of Parkinson's disease - a case-control study of young-onset and old-onset patients. Arch. Neurol., 48, 903-907.
42. Tanner, C.M. (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci., 12, 49-54.
43. Thiruchelvam, M., Brockel, B.J., Richfield, E.K., Baggs, R.B. & Cory-Slachta, D.A. (2000a) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res., 873, 225-234.
44. Thiruchelvam, M., Richfield, E.K., Baggs, R.B., Tank, A.W. & Cory-Slechta, D.A. (2000b) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neuroscience, 20, 9207-9214.
45. Thiruchelvam, M., Richfield, E.K., Goodman, B.M., Baggs, R., Di Monte, D.A. & Cory-Slechta, D.A. (2002) Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology, 23, 621-633.
46. Thiruchelvam, M., McCormack, A., Richfield, E.K., Baggs, R., Tank, A.W., Di Monte, D.A. & Cory-Slechta, D.A. (2003) Age-related irreversible nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci., 18, 589-600.
47. Triarhou, L.C. (1998) Rate of neuronal fallout in a transsynaptic cerebellar model. Brain Res. Bull., 47, 219-222.
48. Widzowski, D.V. & Cory-Slechta, D.A. (1993) Apparent mediation of the stimulus properties of a low dose of quinpirole by dopaminergic autoreceptors. J. Pharmacol. Exp. Ther., 266, 526-534.